227 related articles for article (PubMed ID: 37452493)
21. Dense pattern of embryonal rhabdomyosarcoma, a lesion easily confused with alveolar rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Rudzinski ER; Teot LA; Anderson JR; Moore J; Bridge JA; Barr FG; Gastier-Foster JM; Skapek SX; Hawkins DS; Parham DM
Am J Clin Pathol; 2013 Jul; 140(1):82-90. PubMed ID: 23765537
[TBL] [Abstract][Full Text] [Related]
22. Defective RAGE activity in embryonal rhabdomyosarcoma cells results in high PAX7 levels that sustain migration and invasiveness.
Chiappalupi S; Riuzzi F; Fulle S; Donato R; Sorci G
Carcinogenesis; 2014 Oct; 35(10):2382-92. PubMed ID: 25123133
[TBL] [Abstract][Full Text] [Related]
23. Identification of new genes related to the myogenic differentiation arrest of human rhabdomyosarcoma cells.
Astolfi A; De Giovanni C; Landuzzi L; Nicoletti G; Ricci C; Croci S; Scopece L; Nanni P; Lollini PL
Gene; 2001 Aug; 274(1-2):139-49. PubMed ID: 11675006
[TBL] [Abstract][Full Text] [Related]
24. In vivo imaging of tumor-propagating cells, regional tumor heterogeneity, and dynamic cell movements in embryonal rhabdomyosarcoma.
Ignatius MS; Chen E; Elpek NM; Fuller AZ; Tenente IM; Clagg R; Liu S; Blackburn JS; Linardic CM; Rosenberg AE; Nielsen PG; Mempel TR; Langenau DM
Cancer Cell; 2012 May; 21(5):680-693. PubMed ID: 22624717
[TBL] [Abstract][Full Text] [Related]
25. Identification of PAX3-FKHR-regulated genes differentially expressed between alveolar and embryonal rhabdomyosarcoma: focus on MYCN as a biologically relevant target.
Mercado GE; Xia SJ; Zhang C; Ahn EH; Gustafson DM; Laé M; Ladanyi M; Barr FG
Genes Chromosomes Cancer; 2008 Jun; 47(6):510-20. PubMed ID: 18335505
[TBL] [Abstract][Full Text] [Related]
26. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME
Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756
[TBL] [Abstract][Full Text] [Related]
27. Preclinical rationale for entinostat in embryonal rhabdomyosarcoma.
Bharathy N; Berlow NE; Wang E; Abraham J; Settelmeyer TP; Hooper JE; Svalina MN; Bajwa Z; Goros MW; Hernandez BS; Wolff JE; Pal R; Davies AM; Ashok A; Bushby D; Mancini M; Noakes C; Goodwin NC; Ordentlich P; Keck J; Hawkins DS; Rudzinski ER; Mansoor A; Perkins TJ; Vakoc CR; Michalek JE; Keller C
Skelet Muscle; 2019 May; 9(1):12. PubMed ID: 31113472
[TBL] [Abstract][Full Text] [Related]
28. Expression and activity of vascular endothelial growth factor and metalloproteinases in alveolar and embryonal rhabdomyosarcoma cell lines.
Onisto M; Slongo ML; Gregnanin L; Gastaldi T; Carli M; Rosolen A
Int J Oncol; 2005 Sep; 27(3):791-8. PubMed ID: 16077930
[TBL] [Abstract][Full Text] [Related]
29. PAX7 is a required target for microRNA-206-induced differentiation of fusion-negative rhabdomyosarcoma.
Hanna JA; Garcia MR; Go JC; Finkelstein D; Kodali K; Pagala V; Wang X; Peng J; Hatley ME
Cell Death Dis; 2016 Jun; 7(6):e2256. PubMed ID: 27277678
[TBL] [Abstract][Full Text] [Related]
30. FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcoma.
Milewski D; Shukla S; Gryder BE; Pradhan A; Donovan J; Sudha P; Vallabh S; Pyros A; Xu Y; Barski A; Szabo S; Turpin B; Pressey JG; Millay DP; Khan J; Kalinichenko VV; Kalin TV
Oncogene; 2021 Mar; 40(12):2182-2199. PubMed ID: 33627785
[TBL] [Abstract][Full Text] [Related]
31. p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells.
Ciccarelli C; Marampon F; Scoglio A; Mauro A; Giacinti C; De Cesaris P; Zani BM
Mol Cancer; 2005 Dec; 4():41. PubMed ID: 16351709
[TBL] [Abstract][Full Text] [Related]
32. Bta-miR-885 promotes proliferation and inhibits differentiation of myoblasts by targeting MyoD1.
Elsaeid Elnour I; Dong D; Wang X; Zhansaya T; Khan R; Jian W; Jie C; Chen H
J Cell Physiol; 2020 Oct; 235(10):6625-6636. PubMed ID: 31985035
[TBL] [Abstract][Full Text] [Related]
33. 12-O-tetradecanoylphorbol-13-acetate and EZH2 inhibition: A novel approach for promoting myogenic differentiation in embryonal rhabdomyosarcoma cells.
Marchesi I; Sanna L; Fais M; Fiorentino FP; Giordano A; Bagella L
J Cell Physiol; 2018 Mar; 233(3):2360-2365. PubMed ID: 28722764
[TBL] [Abstract][Full Text] [Related]
34. The methyl-CpG-binding protein CIBZ suppresses myogenic differentiation by directly inhibiting myogenin expression.
Oikawa Y; Omori R; Nishii T; Ishida Y; Kawaichi M; Matsuda E
Cell Res; 2011 Nov; 21(11):1578-90. PubMed ID: 21625269
[TBL] [Abstract][Full Text] [Related]
35. SMAD2 promotes myogenin expression and terminal myogenic differentiation.
Lamarche É; AlSudais H; Rajgara R; Fu D; Omaiche S; Wiper-Bergeron N
Development; 2021 Feb; 148(3):. PubMed ID: 33462116
[TBL] [Abstract][Full Text] [Related]
36. Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics.
Cessna MH; Zhou H; Perkins SL; Tripp SR; Layfield L; Daines C; Coffin CM
Am J Surg Pathol; 2001 Sep; 25(9):1150-7. PubMed ID: 11688574
[TBL] [Abstract][Full Text] [Related]
37. A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations.
Kohsaka S; Shukla N; Ameur N; Ito T; Ng CK; Wang L; Lim D; Marchetti A; Viale A; Pirun M; Socci ND; Qin LX; Sciot R; Bridge J; Singer S; Meyers P; Wexler LH; Barr FG; Dogan S; Fletcher JA; Reis-Filho JS; Ladanyi M
Nat Genet; 2014 Jun; 46(6):595-600. PubMed ID: 24793135
[TBL] [Abstract][Full Text] [Related]
38. The NOTCH1/SNAIL1/MEF2C Pathway Regulates Growth and Self-Renewal in Embryonal Rhabdomyosarcoma.
Ignatius MS; Hayes MN; Lobbardi R; Chen EY; McCarthy KM; Sreenivas P; Motala Z; Durbin AD; Molodtsov A; Reeder S; Jin A; Sindiri S; Beleyea BC; Bhere D; Alexander MS; Shah K; Keller C; Linardic CM; Nielsen PG; Malkin D; Khan J; Langenau DM
Cell Rep; 2017 Jun; 19(11):2304-2318. PubMed ID: 28614716
[TBL] [Abstract][Full Text] [Related]
39. Downregulation of microRNAs miR-1, -206 and -29 stabilizes PAX3 and CCND2 expression in rhabdomyosarcoma.
Li L; Sarver AL; Alamgir S; Subramanian S
Lab Invest; 2012 Apr; 92(4):571-83. PubMed ID: 22330340
[TBL] [Abstract][Full Text] [Related]
40. Cancer-Specific Energy Metabolism in Rhabdomyosarcoma Cells Is Regulated by MicroRNA.
Sugito N; Taniguchi K; Kuranaga Y; Ohishi M; Soga T; Ito Y; Miyachi M; Kikuchi K; Hosoi H; Akao Y
Nucleic Acid Ther; 2017 Dec; 27(6):365-377. PubMed ID: 28981396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
